Fulgent Genetics is a technology company that provides genetic testing and diagnostic services. The company offers a range of genetic tests including oncology, hereditary cancer, known mutation, newborn genetics, and pharmacogenetics.

Fulgent Genetics

Picture Genetics

Our mission is to develop flexible and affordable diagnostics and therapeutics that improve the everyday lives of those around us.

Founded in 2011, Fulgent has evolved into a premier, full-service genomic testing company built around a foundational technology platform. Through our diverse testing menu, Fulgent is focused on transforming patient care in oncology, anatomic pathology, infectious and rare diseases, and reproductive health.

We believe that by providing a wide range of effective, flexible testing options in conjunction with best-in-class service and support, we can redefine the way medicine is managed for patients and clinicians alike.

- Our Products & Services -

Fulgent Genetics
https://www.fulgentgenetics.com/

Fulgent Oncology
https://fulgentoncology.com/

Fulgent BioPharma
https://biopharma.fulgent.com/

Picture Genetics
https://picturegenetics.com/

HelioLiver
https://www.helioliver.com/

Fulgent is a CLIA-certified and CAP-accredited laboratory.

_____________
NASDAQ: FLGT

We’ll be in #NewOrleans next month for the #NSGC24 Annual Conference, where we’re excited to highlight our new #KNOVA Prenatal Cell-Free DNA Screening (NIPT/NIPS) test and our new RNA-Integrated Sequence Evaluation (RISE) service option. 

To chat with us about these or anything else, email info@FulgentGenetics.com and we’ll set up a time to meet in New Orleans! We hope to see you there. 

#PrenatalScreening #NIPT #RISE

#AstraZeneca and #Daiichi Sankyo have made history with the approval of Enhertu in the US! This groundbreaking achievement marks a significant milestone in oncology as Enhertu becomes the first tumor-agnostic HER2-directed therapy for previously treated patients with metastatic HER2-positive solid tumors. 

At Fulgent, we’re eager to support HER2 testing using our state-of-the-art pathology facilities. Reach out to bd@fulgentgenetics.com to learn more.   

Here's to the positive impact Enhertu will have on patients and families worldwide! #Enhertu #Oncology #IHC #HER2 #pathology

We’ll be in Washington D.C. from November 1-5 next week for #ASHG23. Our team will be at booth 510 to talk about the latest in Fulgent BioPharma, Fulgent Oncology, Beacon carrier screening, and more. We’ll also have a presentation about the role of CNV’s in the etiology for chronic kidney disease.

Join us in San Diego from November 1-5 for #SITC at booth 333. We’ll share the latest developments from Fulgent BioPharma and Fulgent Oncology. Be sure to check out our presentations on Nov 4.

Fulgent BioPharma is here at #ASCO24! Let us know if you would like to meet to discuss our oncology biomarker services, including liquid biopsy molecular profiling, solid tumor profiling and more. Contact us for a meeting: http://tiny.cc/Fulgent 

#ASCO #Clinicaltrials #BioPharma #Oncology

Meet up with the Fulgent BioPharma team in Berlin this weekend for #ESHGS2024 #hybridconference. You can find us at stand #386. Talk to our team to learn more about our wide array of NGS tests and lab services, including prenatal testing, hereditary cancer, and more.

DNSSEC

Amazon

Microsoft Exchange Online

DMARC

Office 365 Mail

Microsoft Azure DNS

Amazon Route 53

Amazon S3 CDN

GoDaddy

Chief Commercial Officer

Brandon Perthuis

Product and Marketing Manager

Becky Tsai

Testing Lead

BriAnna Smith

Business Development Manager

Cameron Hsieh

Accounting Manager

Irene Xu, CPA

Senior Manager, Business Development

Jakob Jansson

Senior Manager - Tax

Kevin Tam

Corporate Human Resources Manager

Lorraine Becerra

Regulatory and Quality Compliance Manager

Sarah Lau

Sasha Mison

Health Diagnostics Companies With More Than 10 Employees (Top 10K)

Greater Los Angeles Area Companies With Less Than $50M in Revenue (Top 10K)

Western US Biotechnology Companies

Health Diagnostics Companies With Less Than $50M in Revenue (Top 10K)

Fulgent Diagnostics specializes in genetic testing, panel testing, cancer panel, cancer testing, single genes and covid testing services.

Temple City

California

United States

North America

Fulgent Diagnostics

Fulgent Genetics Q2: Core Revenue Grows, but Profitability Is Still an Issue

Fulgent Genetics, Inc., together with its subsidiaries, provides COVID-19, molecular diagnostic, and genetic testing services to physicians and patients in the United States and internationally. The company offers genetic tests comprising Focus and Comprehensive oncology panels tests; Beacon carrier screening panels test for inherited conditions; solid tumor molecular profiling for somatic cancer testing; rapid whole genome testing for children in NICU and PICU; newborn genetic analysis panel; single front-line test to detect ataxia-related variants and repeat expansions through sequencing; picture genetics, a patient-initiated genetic testing; whole exome and clinical exome panel tests; whole genome, mutation, and repeat expansion testing services, as well as research service tests. It also provides next generation sequencing and reverse transcription polymerase chain reaction-based tests, as well as antigen-based diagnostic tests for the detection of SARS-CoV-2. In addition, the company offers flow cytometry, a cell analysis technique providing diagnosis, prognosis, and monitoring of malignancies; fluorescence in-situ hybridization for detecting and locating a specific DNA sequence on a chromosome; immunohistochemistry, an imaging technique used to visualize antigens in cells; cytogenetics, which analyzes the chromosome set for numerical and structural abnormalities; and molecular testing that includes hematopoietic and solid tumor molecular assays. The company serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. Fulgent Genetics has strategic partnership with Helio Health, Inc. to commercialize blood-based early cancer detection tests. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in Temple City, California.

news impact assignment basic	general
public peers	general	Aug 15, 2024 4:04 AM	2ea03b1d
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general
crunchbase trigger	general	Nov 25, 2024 9:06 AM	5023961a
crunchbase profile	general	Nov 25, 2024 11:04 AM	9182f725
li profile	general	Aug 15, 2024 4:04 AM	ed1924e3
translate crunchbase fundingrounds	general	Nov 25, 2024 3:03 PM	097632bd
peers	general	Aug 15, 2024 4:04 AM	b4371a64
news basic	general	Aug 15, 2024 4:04 AM	1ef81eb5
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:FULGENTGENETICS

Fulgent Genetics

Last Close

16.95

22/11 21:00

Market Cap

586.52M

Beta: -

Volume Today

422.85K

Avg: -